A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy

NCT01144195 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials

Collaborators